Annual report pursuant to Section 13 and 15(d)

License and Collaboration Agreements, Viatris License Agreement (Details)

v3.24.0.1
License and Collaboration Agreements, Viatris License Agreement (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 25, 2023
USD ($)
Nov. 06, 2022
USD ($)
Nov. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
Performanceobligation
Dec. 31, 2022
USD ($)
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Revenue recognized       $ 19,049 $ 39,850
Viatris License Agreement [Member]          
Collaboration and License Agreement [Abstract]          
Non-refundable cash payment received     $ 35,000    
Maximum amount of payments receivable for development, regulatory and commercial milestones   $ 130,000      
First potential payments to be received   $ 10,000      
Maximum percentage of tiered royalties receivable       20.00%  
Number of distinct performance obligations | Performanceobligation       2  
Aggregate transaction price to be recognized $ 10,000     $ 40,000  
Period of non-cancellation window agreement   120 days      
Milestone payment included in revenue recognization       10,000  
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Balance as of beginning of period       3,552 0
Revenue recognized       19,049 39,850
Balance as of end of period       1,407 3,552
Viatris License Agreement [Member] | License Transfer Fee [Member]          
Collaboration and License Agreement [Abstract]          
Aggregate transaction price to be recognized       35,000  
Estimated standalone selling price for license agreement   $ 287,800      
Transaction price allocation of ESSP obligations   39,300      
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Revenue recognized       0 (35,000)
Reclassification to accounts receivable related to costs billed under the Viatris License Agreement       (21,194) $ (1,298)
Viatris License Agreement [Member] | Research and Development Services [Member]          
Collaboration and License Agreement [Abstract]          
Aggregate transaction price to be recognized       5,000  
Estimated standalone selling price for license agreement   5,000      
Transaction price allocation of ESSP obligations   $ 700      
Viatris License Agreement [Member] | Sales Milestones [Member]          
Collaboration and License Agreement [Abstract]          
Milestone payment requirements attributed to the FDA's approval       10,000  
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Revenue recognized       $ 0